Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?
- PMID: 32671484
- DOI: 10.1007/s11883-020-00862-8
Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?
Abstract
Purpose of review: In contrast to patients with non-premature atherosclerotic cardiovascular disease (ASCVD), patients with premature ASCVD have not observed a similar decline in cardiovascular mortality and recurrent adverse events. We sought to review the underlying risk factors, potential gaps in medical management, associated outcomes, and tools for risk prognostication among patients with premature ASCVD.
Recent findings: In addition to traditional cardiovascular risk factors (i.e., diabetes, familial hypercholesterolemia), non-traditional risk factors such as chronic inflammatory conditions, recreational drug use, genetics, and pregnancy-related complications play a key role in development and progression of premature ASCVD. Patients with premature ASCVD, and especially women, receive less optimal medical management as compared to their non-premature counterparts. There is an increasing prevalence of cardiovascular risk factors among young adults. Hence, this population remains at an elevated risk for premature ASCVD and subsequent adverse cardiovascular events. Future studies evaluating different risk assessment tools and focusing on young patients across all three major domains of ASCVD are needed.
Keywords: ASCVD; Gender disparity; ICVD; IHD; MI; PAD; Premature ASCVD; Risk prognostication; Young.
Similar articles
-
Recreational substance use among patients with premature atherosclerotic cardiovascular disease.Heart. 2021 Apr;107(8):650-656. doi: 10.1136/heartjnl-2020-318119. Epub 2021 Feb 15. Heart. 2021. PMID: 33589427
-
Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia.J Clin Lipidol. 2023 Jan-Feb;17(1):150-156. doi: 10.1016/j.jacl.2022.11.009. Epub 2022 Nov 22. J Clin Lipidol. 2023. PMID: 36470719
-
Contemporary outcomes studies to identify and mitigate the risk in patients with premature cardiovascular disease.Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):559-570. doi: 10.1080/14737167.2021.1888718. Epub 2021 Feb 17. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33565901 Review.
-
Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia: does one size fit all?Curr Opin Lipidol. 2018 Dec;29(6):445-452. doi: 10.1097/MOL.0000000000000553. Curr Opin Lipidol. 2018. PMID: 30382952 Review.
-
Atherosclerotic Cardiovascular Disease Novel and Traditional Risk Factors in Middle Eastern Young Women. The ANCORS-YW Study.Glob Heart. 2024 Jul 15;19(1):59. doi: 10.5334/gh.1341. eCollection 2024. Glob Heart. 2024. PMID: 39035774 Free PMC article.
Cited by
-
Assessing the Validity of the Criteria for the Extreme Risk Category of Atherosclerotic Cardiovascular Disease: A Nationwide Population-Based Study.J Lipid Atheroscler. 2022 Jan;11(1):73-83. doi: 10.12997/jla.2022.11.1.73. Epub 2021 Aug 18. J Lipid Atheroscler. 2022. PMID: 35118023 Free PMC article.
-
Oral Nanoformulations in Cardiovascular Medicine: Advances in Atherosclerosis Treatment.Pharmaceuticals (Basel). 2024 Jul 10;17(7):919. doi: 10.3390/ph17070919. Pharmaceuticals (Basel). 2024. PMID: 39065770 Free PMC article. Review.
-
Temporal Trends in Incidence of Premature Cardiovascular Disease Over the Past 7 Decades: The Framingham Heart Study.J Am Heart Assoc. 2022 Oct 4;11(19):e026497. doi: 10.1161/JAHA.122.026497. Epub 2022 Sep 29. J Am Heart Assoc. 2022. PMID: 36172970 Free PMC article.
-
Associations Between Estimated Pulse Wave Velocity and Five-Year All-Cause Mortality in Patients with Atherosclerotic Cardiovascular Disease with and without Standard Modifiable Risk Factors: Evidence From NHANES 1999-2016.Clin Epidemiol. 2024 May 28;16:367-377. doi: 10.2147/CLEP.S457054. eCollection 2024. Clin Epidemiol. 2024. PMID: 38827433 Free PMC article.
-
Nitrotyrosine, Nitrated Lipoproteins, and Cardiovascular Dysfunction in Patients with Type 2 Diabetes: What Do We Know and What Remains to Be Explained?Antioxidants (Basel). 2022 Apr 27;11(5):856. doi: 10.3390/antiox11050856. Antioxidants (Basel). 2022. PMID: 35624720 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials